Guideline Summary – Management of Escherichia coli Pneumonia

Clinical Presentation

Rapidly progressive respiratory symptoms (new or worsening cough, sputum, dyspnea, pleuritic chest pain) with high fever and chills are typical at presentation [@1].
Systemic signs such as hypotension, tachypnea, tachycardia, and altered mental status are common, especially in elderly patients [@1].
Tachypnea (respiratory rate ≥ 30 breaths/min) correlates with disease severity [@1].
Hypoxemia (SpO₂ < 92 % on room air) frequently accompanies respiratory distress [@1].
Fever > 38 °C may be absent in older or immunocompromised patients [@1].

Multilobar infiltrates on chest radiograph are associated with increased severity and poorer prognosis [@1].
Pleural effusions may develop and should be evaluated when clinical response is suboptimal [@1].
Radiographic resolution lags behind clinical improvement; only ~60 % of otherwise healthy patients < 50 years achieve complete clearing by 4 weeks [@1].
Computed tomography (CT) demonstrates multiple cavitary lesions that are characteristic of E. coli pneumonia [@2].
Cavities often contain fluid collections (necrotizing pneumonia) and may be bilateral [@2].
Contrast‑enhanced CT is essential for assessing cavitary disease and detecting complications [@2].
Cavities adjacent to the pleura carry a heightened risk of rupture, leading to pneumothorax or pyopneumothorax [@2].

* E. coli strains produce toxins and enzymes that cause necrotizing inflammation of lung parenchyma [@2].

Immunocompromised status (e.g., HIV CD4 < 250 cells/µL, chemotherapy, immunosuppressive drugs) markedly increases the risk of severe pneumonia and cavity formation [@2].
Advanced age (≥ 65 years) is a major predisposing factor due to reduced immune function and impaired mucociliary clearance [@1].
Pre‑existing lung disease (bronchiectasis, prior tuberculosis) predisposes to cavity formation [@2].

For hospitalized non‑ICU patients with moderate‑severity pneumonia, ceftriaxone 1–2 g IV daily plus azithromycin 500 mg IV daily is the standard regimen [@3][@4].
The first dose should be administered within 8 hours of presentation; delays beyond this window increase 30‑day mortality by 20–30 % [@3].
In ICU‑level severe pneumonia, ceftriaxone 2 g IV daily plus azithromycin 500 mg IV daily is mandatory [@3].
β‑lactam monotherapy is associated with higher mortality; combination therapy is required for all ICU patients [@3].
For septic shock, initiate aggressive fluid resuscitation (30 mL/kg crystalloid within 3 hours) and add vasopressors as needed [@3].

Ampicillin‑sulbactam 3 g IV every 6 h for 21 days is recommended when aspiration or lung abscess is suspected [@2].
Ertapenem 1 g IV daily or meropenem 1 g IV every 8 h should be used for ESBL‑producing E. coli or when treatment failure occurs [@3].
Piperacillin‑tazobactam 4.5 g IV every 6 h is appropriate for patients with risk factors for Pseudomonas (e.g., structural lung disease, recent hospitalization with IV antibiotics) [@3].

A minimum of 21 days of antimicrobial therapy is required for cavitary E. coli pneumonia [@2].
Amoxicillin‑clavulanate IV 2 g every 6 h for 21 days is recommended when cavitary lesions are present [@2].

Switch to oral antibiotics once the patient is hemodynamically stable (SBP ≥ 90 mmHg, HR ≤ 100 bpm), clinically improving, afebrile for 48–72 h, respiratory rate ≤ 24 breaths/min, SpO₂ ≥ 90 % on room air, and able to take oral medication [@3].
Oral step‑down options include amoxicillin 1 g three times daily or amoxicillin‑clavulanate 875/125 mg twice daily [@3].
Minimum 5 days of therapy for uncomplicated pneumonia, continuing until afebrile for 48–72 h with ≤ 1 sign of instability [@3].
14–21 days for bacteremic E. coli pneumonia or severe disease [@3].

Monitor temperature, respiratory rate, pulse, blood pressure, mental status, and oxygen saturation at least twice daily [@1].
If no clinical improvement by day 2–3, obtain repeat chest radiograph, inflammatory markers (CRP, WBC), and consider chest CT to evaluate for complications [@1][@2].
Obtain blood cultures and respiratory specimens before initiating antimicrobial therapy [@2].
Pleural effusion: perform diagnostic thoracentesis if large or patient appears toxic; drain if pH < 7.2, glucose < 40 mg/dL, LDH > 1000 IU/L, frank pus, or positive Gram stain [@4][@2].
Hemoptysis may require bronchial artery embolization or surgical intervention [@2].
Pyopneumothorax mandates chest‑tube drainage and surgical consultation [@2].
Fungal superinfection (e.g., Aspergillus) in cavities should be treated with appropriate antifungal agents [@2].

Do not use fluoroquinolone monotherapy empirically because of high resistance rates in E. coli pneumonia.
Do not delay antibiotics while awaiting culture results; therapy must start promptly [@3].
Do not use macrolide monotherapy in hospitalized patients, as it fails to cover gram‑negative organisms such as E. coli [@3].